HIV vaccine - Institute of Human Virology/Profectus Biosciences

Drug Profile

HIV vaccine - Institute of Human Virology/Profectus Biosciences

Alternative Names: AIM Therapy - Profectus BioScience; anti-HIV antibodies - Profectus BioScience; FLSC vaccine; Full-length single chain vaccine; IHV 001; IHV 01

Latest Information Update: 13 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Profectus Biosciences
  • Developer Institute of Human Virology; Profectus Biosciences
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 23 Apr 2018 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV Infections (In volunteers) in USA , (NCT03505060)
  • 01 Oct 2015 Phase-I clinical trials in HIV infections (In volunteers, Prevention) in USA (Parenteral) (9185545; NCT02756208)
  • 19 Jul 2007 Profectus BioSciences receives SBIR grant from National Institute of Allergy and Infectious Diseases for Anti-HIV antibodies development in HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top